High SGK1 levels linked to depression, trauma
High SGK1 levels linked to depression and childhood trauma; inhibitors show promise in mice.
Why it matters
- Depression affects millions globally, with many cases resistant to current treatments.
- SGK1 inhibitors could offer new treatment options.
- Potential for genetic screening to identify high-risk individuals.
By the numbers
- 5.7% of global adults (332 million people) experience depression.
- 60% of people with major depression and two-thirds of suicide attempt survivors faced childhood trauma.
- High SGK1 levels found in depression patients and suicide victims, highest in those with childhood trauma.
The big picture
- SGK1 inhibitors in development for other conditions could speed up depression treatment advancements.
- Targeted treatments for those with childhood trauma and depression could be on the horizon.
What they're saying
- Researchers highlight the urgency to treat those at high risk of depression and suicide due to childhood trauma.
- People with treatment-resistant depression express hope for new treatment options.
Caveats
- Research is in early stages with mouse models; human trials needed.
- SGK1 has other functions, so inhibiting it might have side effects.
What’s next
- Further research and human trials needed to confirm findings and develop treatments.
- Potential for genetic screening to identify at-risk individuals.